ST-266 is under clinical development by Noveome Biotherapeutics and currently in Phase I for Trigeminal Neuralgia (Tic Douloureux). According to GlobalData, Phase I drugs for Trigeminal Neuralgia (Tic Douloureux) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ST-266’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ST-266 overview

ST-266 is under development for the treatment of ocular hypertension, radiation-induced dermatitis, dry eye syndrome, periodontitis and optic neuritis, the most common presenting sign of multiple sclerosis (MS), necrotizing enterocolitis, cataract surgery complications (ophthalmology), erythema, glaucoma, Trigeminal Neuralgia (Tic Douloureux), chronic traumatic encephalopathy (CTE), diabetic retinopathy, diabetic macular edema, age-related macular degeneration (AMD). The drug candidate is administered through ophthalmic, topical, intraocular, buccal, nasal and lingual routes of administration. It is an amniotic membrane derived cellular cytokine solution (ACCS). It is developed based on a proprietary technology platform derived from human placental cells. The drug candidate was also under development for the treatment of deep burns (diabetic subjects), and partial thickness burns (non-diabetics subjects).

It is also under development for the treatment of gingivitis, allergic conjunctivitis, emphysema, cytokine storm (CS) in patients caused by the coronavirus disease (COVID-19), traumatic brain injury, persistent corneal epithelial defects and optic nerve/retinal diseases and injuries.

Noveome Biotherapeutics overview

Noveome Biotherapeutics formerly Stemnion, is a biopharmaceutical company advancing ST266, a multi-targeted secretome containing biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. Noveome Biotherapeutics is headquartered in Pittsburgh, Pennsylvania, the US.

For a complete picture of ST-266’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.